Pentasa Sachets 2 g Prolonged release granules.
PDF Leaflet Revision Date: 7 January 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mild to moderate ulcerative colitis and Crohnu2019s disease.
Dosage (summary)
Adults: Up to 4 g daily; Maintenance: 2 g daily. Children: 30-50 mg/kg/day, max 4 g.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use with caution; potential risks in pregnancy and breastfeeding.
Key Drug Interactions
- Azathioprine
- NSAIDs
- Warfarin
Contraindications
- Hypersensitivity to mesalazine
- Severe liver impairment
- Severe renal impairment
Common side effects
- Diarrhoea
- Nausea
- Abdominal pain
- Headache
- Rash
Counselling Points
- Do not chew granules
- Stay hydrated
- Report severe skin reactions
- Monitor for renal function
Serious warnings
- Severe cutaneous adverse reactions
- Renal function monitoring required
- Risk of blood dyscrasias
Important Disclaimer
The Pentasa Sachets 2 g Prolonged release granules. professional information leaflet below is the property of Ferring International Center Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
